Clinical Trials in Tennessee

Showing 2661-2680 of 17,345 trials

Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT00983463

Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease in the United States. The incidence of NAFLD is very similar to that of obesity, type 2 diabetes, and the metabolic syndrome. The investigators hypothesize that there may be a relationship between over-nutrition, decreased physical activity and the development of fatty liver. The purpose of this study is to identify the types of fats and proteins, and the quantity of each, that are associated with increased severity of NAFLD.

Nonalcoholic Fatty Liver Disease

Vanderbilt University45 participantsStarted Oct 2009

Nashville, Tennessee, United States

Active Not RecruitingPhase 329 miles

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.

Metastatic Prostate CancerProstate Adenocarcinoma

Exelixis575 participantsStarted Oct 2020

Tucson, Arizona, United States • Duarte, California, United States • Fullerton, California, United States +277 more locations

Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Find Trials by Condition in Tennessee

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

SyncAV Post-Market Trial

Blue Light Cystoscopy With Cysview® Registry

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Multisite Virtual Reality Intervention for Speech Anxiety

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations

Study of Aspirin in Patients With Vestibular Schwannoma

An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)